C4 (CCCC) Up 6% on Restructuring Plan to Curb Cash Burn [Yahoo! Finance]
C4 Therapeutics, Inc. (CCCC)
NASDAQ:AMEX Investor Relations:
ir.chinacache.com
Company Research
Source: Yahoo! Finance
CCCC seeks to prioritize the advancement of two of its pipeline candidates, CFT7455 and CFT1946, both of which are in early-stage development. While CFT7455 is being developed in a phase I/II study for multiple myeloma (MM) and non-Hodgkin's lymphoma (NHL) indications, CFT1946 is being evaluated in a separate phase I/II study for treating BRAF V600 mutant solid tumors including non-small cell lung cancer (NSCLC), colorectal cancer and melanoma. The company also intends to advance its partnered programs. It intends to support its partner, China-based Betta Pharmaceuticals, in initiating clinical development on CFT8919 in EGFR L858R mutated NSCLC patients. C4T also plans on expanding its collaborations with Merck MRK, Biogen and Roche. To achieve these objectives, C4 Therapeutics will reduce its existing workforce by 30%. It reported about $330 million in unaudited cash, cash equivalents and marketable securities as of Jan 5, compared with $246.4 million balance as of Sep 30, 2023.
Show less
Read more
Impact Snapshot
Event Time:
CCCC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CCCC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CCCC alerts
High impacting C4 Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CCCC
News
- C4 Therapeutics to Participate in the Stifel 2024 Targeted Oncology ForumGlobeNewswire
- C4 Therapeutics Presents New Preclinical Data for CFT1946 Highlighting Superior Activity as a Single Agent to Clinically Approved BRAF Inhibitor Standard of Care Combinations at the American Association for Cancer Research Annual Meeting 2024 [Yahoo! FinaYahoo! Fina
- C4 Therapeutics Presents New Preclinical Data for CFT1946 Highlighting Superior Activity as a Single Agent to Clinically Approved BRAF Inhibitor Standard of Care Combinations at the American Association for Cancer Research Annual Meeting 2024GlobeNewswire
- Here's Why Meridian Small Cap Growth Fund Trimmed C4 Therapeutics (CCCC) [Yahoo! Finance]Yahoo! Finance
- Synovial Sarcoma Treatment Market Size to Reach USD 1,144.84 Mn by 2033 [Yahoo! Finance]Yahoo! Finance
CCCC
Earnings
- 11/1/23 - Beat
CCCC
Sec Filings
- 4/10/24 - Form 4
- 4/10/24 - Form SC
- 4/2/24 - Form 4
- CCCC's page on the SEC website